Title:Smoking Affects the Predictive Roles of Antioxidant Enzymes in the
Clinical Response to Risperidone in Schizophrenia: A Large-scale Cohort
Study
Volume: 21
Issue: 10
Author(s): Meihong Xiu, Xiuli Song, Hanlun Yang, Xingjuan Huang, Fengchun Wu*Xiangyang Zhang*
Affiliation:
- Department of Psychiatry, The
Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
- Department of Biomedical Engineering,
Guangzhou Medical University, Guangzhou, China
- Guangdong Engineering Technology Research Center for
Translational Medicine of Mental Disorders, Guangzhou, China
- Department of Psychiatry, The
Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
- CAS Key Laboratory of Mental Health, Institute of
Psychology, Beijing, China
Keywords:
Schizophrenia, tobacco smoke, risperidone, antioxidant enzyme activity, CAT activities, positive and negative syndrome scale (PANSS).
Abstract:
Objectives: There is overwhelming evidence of the relationship between smoking and
schizophrenia (SZ). Tobacco smoke is considered to ameliorate the symptoms and reduce the side effects
of antipsychotics in SZ patients. However, the underlying biological mechanism by which tobacco
smoke improves symptoms in SZ remains unclear. This study was designed to examine the effects
of tobacco smoke on antioxidant enzyme activities and psychiatric symptoms after receiving 12-week
risperidone monotherapy.
Methods: Two hundred and fifteen antipsychotic-naïve first-episode (ANFE) patients were recruited
and treated with risperidone for 3 months. The severity of the patient’s symptoms was assessed by the
Positive and Negative Syndrome Scale (PANSS) at baseline and at post-treatment. Plasma SOD,
GSH-Px, and CAT activities were determined at baseline and follow-up.
Results: Relative to nonsmoking patients with ANFE SZ, patients who smoked had higher baseline
CAT activity. In addition, among non-smokers with SZ, baseline GSH-Px was associated with clinical
symptom improvement, while baseline CAT was associated with positive symptom improvement in
smokers with SZ.
Conclusion: Our findings demonstrate that smoking affects the predictive role of baseline SOD, GSHPx,
and CAT activities on clinical symptom improvement in patients with SZ.
